| Literature DB >> 35611255 |
Arash Sarveazad1,2, Mansour Bahardoust1,3, Jebreil Shamseddin4, Mahmoud Yousefifard5.
Abstract
Anal fistula refers to a clinical condition with local pain and inflammation associated with purulent discharge that affects the quality of life. Due to the lack of studies, the presence of bias, and high heterogeneity in the studies, the present systematic review is the first to be performed on the population-based database in this field. The present systematic review and meta-analysis was performed according to MOOSE guidelines. After systematic searching in electronic databases, only four articles met the inclusion criteria. After preparing a checklist and extracting data from the relevant articles, a meta-analysis was performed. All studies on the prevalence of anal fistula are related to Europe, and so far, no study has been conducted on other continents. The overall prevalence of anal fistula in European countries was 18.37 (95% CI: 18.20-18.55%) per 100,000 individuals, and the highest prevalence was reported for Italy (23.20 (95% CI: 22.82 to 23.59) per 100,000 people). From the present population-based (224,097,362) study results, it can be concluded that there is a prominent knowledge gap in this context. Because all the studies included in the current study relate only to Europe, the need for further research in this field in other countries is inevitably sensible. ©2022 RIGLD, Research Institute for Gastroenterology and Liver Diseases.Entities:
Keywords: Anal Fistulas; Prevalence; Systematic Review.
Year: 2022 PMID: 35611255 PMCID: PMC9123633
Source DB: PubMed Journal: Gastroenterol Hepatol Bed Bench ISSN: 2008-2258
Key questions and NHLBI quality control tool items
| 1. Was the research question or objective in this paper clearly stated? |
| 2. Was the study population specified and defined? |
| 3. Was the participation rate of eligible persons at least 50%? |
| 4. Were all the subjects selected or recruited from the same or similar populations (including the same period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? |
| 5. Was a sample size justification, power description, or variance and effect estimates provided? |
| 6. For the analyses in this paper, were the exposure(s) of interest measured before the outcome(s) being measured? |
| 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? |
| 8. For exposures that can vary in amount or level, did the study examine different exposure levels related to the outcome (e.g., categories of exposure or exposure measured as a continuous variable)? |
| 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? |
| 10. Was the exposure(s) assessed more than once over time? |
| 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? |
| 12. Were the outcome assessors blinded to the exposure status of participants? |
| 13. Was the loss to follow-up after baseline 20% or less? |
| 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? |
Figure 1Flowchart of the present study
Quality control of imported articles
| Item | Cuschieri; 2001 | Hokkanen; 2019 | Sainio; 1984 | Zanotti; 2007 |
|---|---|---|---|---|
| 1. Was the research question or objective in this paper clearly stated? | Yes | Yes | Yes | Yes |
| 2. Was the study population specified and defined? | Yes | Yes | Yes | Yes |
| 3. Was the participation rate of eligible persons at least 50%? | Yes | Yes | NR | Yes |
| 4. Were all the subjects selected or recruited from the same or similar populations (including the same period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | Yes | Yes | Yes | Yes |
| 5. Was a sample size justification, power description, or variance and effect estimates provided? | No | No | No | No |
| 6. For the analyses in this paper, were the exposure(s) of interest measured before the outcome(s) being measured? | NA | NA | NA | NA |
| 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | Yes | Yes | Yes | Yes |
| 8. For exposures that can vary in amount or level, did the study examine different exposure levels related to the outcome (e.g., categories of exposure or exposure measured as a continuous variable)? | NA | NA | NA | NA |
| 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | Yes | Yes | Yes | Yes |
| 10. Was the exposure(s) assessed more than once over time? | NA | NA | NA | NA |
| 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | Yes | Yes | Yes | Yes |
| 12. Were the outcome assessors blinded to the exposure status of participants? | No | No | No | No |
| 13. Was the loss to follow-up after baseline 20% or less? | NR | NR | NR | NR |
| 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | NA | NA | NA | NA |
NA: Not applicable; NR: Not reported
Figure 2Publication bias between included studies
Figure 3Forest plot the overall prevalence of anal fistula in the general population
Figure 4Prevalence of anal fistula by year of data collection
Figure 5Prevalence of anal fistula by study countries. The prevalence is estimated as the number of patients per 100,000 population. Data are reported to be prevalent with a 95% confidence interval
Prevalence of anal fistula by study countries
| Region and recruitment period | Prevalence | 95% confidence interval | |
|---|---|---|---|
| European countries; 1980-1994 | 2.84 | 2.57 | 3.13 |
| Finland; 1969-1978 | 8.6 | 6.4 | 11.55 |
| Spain; 2001 | 10.4 | 9.88 | 10.95 |
| UK; 2004, and 2014-2017 | 20.76 | 20.06 | 21.47 |
| Germany; 2002 | 20.2 | 19.9 | 20.51 |
| Italy; 2002 | 23.2 | 22.82 | 23.6 |
The prevalence is estimated as the number of patients per 100,000 population
Characteristics of the entered studies
| Study | Recruitment period | Country | Population coverage* | Study design | Age group | Male number | Number of fistulae |
|---|---|---|---|---|---|---|---|
| Cuschieri; 2001 | 1980-1994 | European countries | 4.60 | Registry survey | Newborns | NR | 72 |
| 359 | |||||||
| 47 | |||||||
| Hokkanen; 2019 | 2014 | UK | 4.88 | Registry survey | Children and adult | NR | 1143 |
| 2015 | UK | 4.22 | 938 | ||||
| 2016 | UK | 3.57 | 688 | ||||
| 2017 | UK | 3.17 | 579 | ||||
| Sainio; 1984 | 1969-1978 | Finland | 0.51 | Retrospective analysis | Children and adult | 288 | 458 |
| Zanotti; 2007 | 2004 | England | 49.56 | Registry survey | Children and adult | NR | 9104 |
| 2002 | Germany | 82.54 | 16645 | ||||
| 2002 | Italy | 56.99 | 13231 | ||||
| 2001 | Spin | 14.05 | 1458 |
*, Numbers are presented in a million population